FXR & LXR

Bacterial type II fatty acid synthesis (FAS-II) is mediated by a series of enzymes, each of which may be targeted by potential antibiotics.

Tauro-obeticholic acid is a taurine-conjugated form of obeticholic acid, which is a farnesoid X receptor (FXR) agonist and semisynthetic derivative of chenodeoxycholic acid.

Tauro-α-muricholic acid (TαMCA) is an antagonist of the farnesoid X receptor (FXR; IC50 = 28 μM) and a taurine-conjugated form of the murine-specific primary bile acid α-muricholic acid.

Tauro-β-muricholic Acid (sodium salt) is a reversible, competitive farnesyl X receptor (FXR) antagonist (IC 50 = 40μM).

A neuropeptide with diverse biological activities

Chenodeoxycholic Acid-d4 is a bile acid analog labeled with deuterium (d4) and is commonly used as a substrate in targeted metabolomics.

A metabolite of CDCA

A dual agonist of FXR and PPARδ

A dual agonist of LXRα and LXRβ

An internal standard for the quantification of tauro-α-muricholic acid

An internal standard for the quantification of tauro-β-muricholic acid

A metabolite of CDCA

EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC50 values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells).

Larsucosterol (DUR-928) trimethylamine, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol trimethylamine as a potent endogenous regulator decreases lipogenesis. Larsucosterol trimethylamine inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1.

FXR agonist 5 (compound 1) is a type of FXR activator. FXR agonist 5 can be used to study diseases or disorders caused by metabolic inflammation.

NDB is a selective antagonist of human FXRα (hFXRα) that can effectively regulate the transcription of downstream genes of FXRα. NDB can be used in anti-diabetes research.

Omesdafexor is a FXR agonist.

FXR antagonist 1 (compound F6) is an orally active and selective intestinal FXR antagonist (IC50=2.1 μM).

FXR agonist 3 is an anti-NASH agent, acting by activating FXR.

HEC96719 is a selective and orally active tricyclic farnesoid X receptor (FXR) agonist with EC50 values of 1.37 and 1.55 nM, respectively.

ACT001 (Dimethylaminomicheliolide; DMAMCL) hydrochloride is an orally active, blood-brain barrier-permeable anti-inflammatory and anti-tumor agent.